

Prevention of Artificial Joint Infections

Erin Tsou, Pharm D,
PGY-2 Resident, Infectious Diseases

John Engelbert, Pharm D BCIPD,
Infectious Diseases Pharmacist



Objectives


- Discuss risk and consequences of orthopedic infections (prosthetic joint infections)
- Discuss bacterial resistance and potential impact on post op infections
- Discuss best practice and impact of pre-op screening and preparation prior to surgery
- Discuss optimal use and timing of antimicrobial therapy to prevent post-op infections






Prosthetic Joint Infections (PJI)

- Treatment requires antimicrobial therapy, surgery or both
- Antimicrobial therapy often requires several weeks of IV and oral antibiotics and sometimes given in bone cement in a “two stage” replacement.
- Often develop bone infection (osteomyelitis)




Incidence of Prosthetic Joint Infections

Figure 39: Most Frequently Reported ICD-9 Diagnosis Codes for Early Knee Revisions (<3 Months to Revision) (N=268)



AJRR 2014 annual report





Prosthetic Joint Infections (PJI)

- Incidence by procedure
 - 0.5-2.0% in knees
 - 0.5-1.0 % in Hips
 - < 1.0 % in Shoulder
- Incidence in the United States fell from 1.4% to in 2002-2006 to 0.76% from 2011 from 2014.
- Usually occurs in the first two years post joint replacement.





Risk factors (PJI)


- Co-morbid conditions (Rheumatoid Arthritis, Diabetes mellitus, kidney disease, obesity).
- Use of corticosteroids (prednisone) and biologic disease modifying anti-rheumatics.
- Prior or second orthopedic surgery.
- Methicillin Resistant Staph Aureus





Organisms that Cause PJI

- Coagulase-negative staph and *S. aureus* are the most common organism in the US¹
- 10% cases are culture (-)
- Most challenging are MRSA and methicillin-resistant coagulase-negative staph species²
 - More than half of PJIs in some institutions
- Gram-negative and polymicrobial (MRSA and anaerobes) (5-23%)



1. Del Pozo JL, et al. *NEJM*. 2009;361(8):784-94.
2. Parvizi J, et al. *JOA*. 2010;25(6)(suppl):103-7.






Prosthetic Joint Infections

Two-Stage Exchange Arthroplasty

MRSA infections 10 times
(OR) more likely to fail¹



1. Salgado C, et al. *CORR*. 2007;461:48-53
2. Image: en.Wikipedia.org



Prosthetic Joint Infections

PREVENTION





Several Strategies for prevention


- Staph aureus decolonization
 - Both MSSA and MRSA nasal screening
 - Mupirocin ointment nasal decolonization (apply into each nostril twice daily for 5-10 days prior to surgery)
 - Consider on discharge form hospital if known MRSA.
- Chlorhexidine bathing prior to surgery
- Betadine Nasal swabs on admission



Nasal Decolonization for Staph



Chlorhexidine Bathing





Antimicrobial Prophylaxis –Screening for MRSA History

Table 3. Results of Multivariate Logistic-Regression Analyses to Identify Potential Risk Factors for MRSA Infection.*

Characteristic	Adjusted Odds Ratio (95% CI)*
Race	
Non-Hispanic white	1.0†
Non-Hispanic black	1.9 (1.1–3.4)
Other	0.3 (0.1–1.0)
Use of any antibiotic in past mo (vs. no use)	2.4 (1.3–4.3)
Reported spider bite (vs. other cause of infection)	3.0 (1.6–5.7)
Underlying illness (vs. no underlying infection)	0.3 (0.2–0.6)
History of MRSA infection (vs. absence of such history)	3.4 (1.1–10)
Close contact with person with similar infection (vs. no close contact)	3.8 (1.6–9.3)

* Estimates were adjusted for all other variables in the table. CI denotes confidence interval.


† This group served as the reference group for other race variables.





Antibiotics for Prophylaxis

- Approximately 5% of patients in U.S. hospitals carry MRSA in their nose or on their skin
- If no risk factors or history of MRSA a single antibiotic (Cefazolin) is considered adequate
- If at risk for MRSA give Vancomycin **AND** Cefazolin as Cefazolin has better activity against Methicillin Sensitive Staph Aureus (MSSA) than Vancomycin





Comparative Study

> Clin Orthop Relat Res. 2012 Oct;470(10):2702-7.

doi: 10.1007/s11999-012-2255-1.

Does dual antibiotic prophylaxis better prevent surgical site infections in total joint arthroplasty?

Amy Sewick¹, Amun Makani, Chia Wu, Judith O'Donnell, Keith D Baldwin, Gwo-Chin Lee

Affiliations + expand

PMID: 22290130 PMCID: [PMC3441989](#) DOI: [10.1007/s11999-012-2255-1](#)

Free PMC article





Does Dual Antibiotic Prophylaxis Better Prevent Surgical Site Infections in Total Joint Arthroplasty?

Sewick A et al. *Clin Orthop Relat Res.* 2012;470(10):2702-2707

- Retrospectively reviewed 1,828 primary total joint arthroplasties (TJAs)
- Intervention:
 - Dual antibiotic regimen of cefazolin + vancomycin vs. cefazolin alone
- Objective:
 - To determine the rate of surgical site infections (SSIs) as well as the microbiology of subsequent SSIs
- Outcome:
 - Total of 22 SSIs (1.2%) with no significant difference in the infection rate between the dual antibiotic prophylaxis group compared to the single antibiotic regimen (1.1 and 1.4% respectively, $p = 0.636$)
 - While addition of vancomycin did not decrease the rate of SSIs, it did decrease the incidence of MRSA infections (0.08 vs. 0.8% $p = 0.022$), but with a high number needed to treat (NNT = 138)






ORIGINAL ARTICLE

Trial of Vancomycin and Cefazolin as Surgical Prophylaxis in Arthroplasty

Trisha N. Peel, M.B., B.S., Ph.D., Sarah Astbury, B.Nurs., Allen C. Cheng, M.B., B.S., M.Biostat., Ph.D., David L. Paterson, M.B., B.S., Ph.D., Kirsty L. Busing, M.B., B.S., M.D., Tim Spelman, M.B., B.S., Ph.D., An Tran-Duy, Ph.D., Sam Adie, M.B., B.S., M.P.H., Ph.D., Glenn Boyce, M.B., B.S., Catherine McDougall, M.B., B.S., Robert Molnar, M.B., B.S., Jonathan Mulford, M.B., B.S., et al., for the ASAP Trial Group*



4239 patients
4113 in mITT
1^o or revision surgery
54% knee, 45% hip

Cefazolin + NS placebo
Cefazolin + 1.5g vancomycin


11 Australian centers
from 2019-2021





ASAP Trial – Primary Outcome

Surgical-Site Infection within 90 Days after Surgery




SSI within 90 days of surgery
3.5% placebo vs 4.5% vanco
(RR 1.28, 95%CI 0.94-1.73, p = 0.11)





ASAP Trial – Secondary Outcomes





ASAP Trial Conclusions

- **Vancomycin was not superior** to placebo in combination with cefazolin for the prevention of surgical site infections in joint arthroplasty and was associated with an increased incidence of infection in knee arthroplasty surgery
 - **Only 24 patients out of the ~4,000** had history of MRSA colonization
 - Vancomycin group has more SSI but less AKI - difficult to make sense of
- Hypersensitivity Secondary Outcome
 - Hypersensitivity reactions more than doubled in the vancomycin group
 - Vancomycin infusion reactions – many providers only worry about penicillin allergies and the possibility of cross-reactivity with cefazolin
- Overall – **Use Cefazolin alone if no history of MRSA as Vancomycin unlikely to add any benefit in reducing the risk of SSI in the absence of MRSA colonization**





Antibiotic Allergy Considerations

- Cross-reactivity between penicillins and cephalosporins is not a class effect but an allergic reaction to antibiotics with **similar side chains** in their chemical structure



Table 1: Penicillin and other beta-lactams (If allergy to a specific antibiotic, avoid use if similar class and/or side chain)

Avoid antibiotics in the same column if true allergy due to risk of same class or similar side-chain cross-reactivity							
Penicillin	Penicillin Amoxicillin Ampicillin Ampicillin-Sulbactam Piperacillin-Tazobactam						
Cephalosporin	Cephalexin Cefadroxil Cefaclor	Cefazolin	Cefotetan	Cefoxitin Cefotaxime Ceftriaxone Cefepime Cefpodoxime Cefuroxime	Ceftaroline	Ceftazidime Cefiderocol	
Monobactam						Aztreonam	
Carbapenem							Ertapenem Meropenem Imipenem Doripenem

(+) Known cross-reactive (X) Similar or same side chain	Penicillin	Amoxicillin	Ampicillin	Cephalexin	Cefazolin	Cefuroxime	Cefoxitin	Ceftriaxone	Cefotaxime	Ceftazidime	Cefepime	Cefiderocol	Aztreonam
Penicillin		+	+	+									
Amoxicillin	+		+	+									
Ampicillin	+	+		X									
Cephalexin	+	+	X										
Cefazolin													
Cefuroxime							X	X	X		X		
Cefoxitin							X						
Ceftriaxone							X		X		X		
Cefotaxime							X	X			X		
Ceftazidime												X	X
Cefepime							X	X	X				
Cefiderocol											X		X
Aztreonam										X		X	



Cefazolin has a Completely Dissimilar Side Chain from all Penicillins





Palomar Surgical Prophylaxis Guidelines

Vancomycin alone only if cefazolin allergy



ANTIBIOTIC PROPHYLAXIS Surgery and Procedures

Antibiotic Selection *

Specialty/Procedure	First Line	Penicillin Allergy	Severe Penicillin or First Line Med Allergy **
NEUROSURGERY	cefazolin	cefazolin	vancomycin
SPINE: lumbar discectomy (may not need abx)	cefazolin +/- vancomycin	Cefazolin +/- vancomycin	vancomycin
SPINE (other than lumbar discectomy)	Cefazolin +/- vancomycin***	Cefazolin +/-vancomycin***	vancomycin
ORTHO: ORIF closed or open fx (Gustilo type I or II)	cefazolin	cefazolin	vancomycin
ORTHO: ORIF open (Gustilo Type III)	cefazolin & gentamicin	cefazolin & gentamicin	vancomycin & gentamicin
ORTHO: Joint Replacement (primary or revision without infection)	Cefazolin +/- vancomycin ***	cefazolin +/- vancomycin ***	vancomycin
ORTHO: Revision Joint Replacement with INFECTION	MD discretion	MD discretion	MD discretion



Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017

Sandra I. Berríos-Torres, MD; Craig A. Umscheid, MD, MSCE; Dale W. Bratzler, DO, MPH; Brian Leas, MA, MS; Erin C. Stone, MA; Rachel R. Kelz, MD, MSCE; Caroline E. Reinke, MD, MSHP; Sherry Morgan, RN, MLS, PhD; Joseph S. Solomkin, MD; John E. Mazuski, MD, PhD; E. Patchen Dellinger, MD; Kamal M. F. Itani, MD; Elie F. Berbari, MD; John Segreti, MD; Javad Parvizi, MD; Joan Blanchard, MSS, BSN, RN, CNOR, CIC; George Allen, PhD, CIC, CNOR; Jan A. J. W. Kluytmans, MD; Rodney Donlan, PhD; William P. Schecter, MD; for the Healthcare Infection Control Practices Advisory Committee

Parenteral Antimicrobial Prophylaxis

IA.1. Administer preoperative antimicrobial agents only when indicated based on published clinical practice guidelines and timed such that a bactericidal concentration of the agents is established in the serum and tissues when the incision is made. (Category IB–strong recommendation; accepted practice.)

IA.2. No further refinement of timing can be made for preoperative antimicrobial agents based on clinical outcomes. (No recommendation/unresolved issue.)

IB. Administer the appropriate parenteral prophylactic antimicrobial agents before skin incision in all cesarean section procedures. (Category IA–strong recommendation; high-quality evidence.)

IC. The literature search did not identify randomized controlled trials that evaluated the benefits and harms of weight-adjusted parenteral antimicrobial prophylaxis dosing and its effect on the risk of SSI. Other organizations have made recommendations based on observational and pharmacokinetic data, and a summary of these recommendations can be found in the Other Guidelines section of the narrative summary for this question (eAppendix 1 of the Supplement). (No recommendation/unresolved issue.)

1D. The search did not identify sufficient randomized controlled trial evidence to evaluate the benefits and harms of intraoperative re-dosing of parenteral prophylactic antimicrobial agents for the prevention of SSI. Other organizations have made recommendations based on observational and pharmacokinetic data, and a summary of these recommendations can be found in the Other Guidelines section of the narrative summary for this question (eAppendix 1 of the Supplement). (No recommendation/unresolved issue.)

1E. In clean and clean-contaminated procedures, do not administer additional prophylactic antimicrobial agent doses after the surgical incision is closed in the operating room, even in the presence of a drain. (Category IA–strong recommendation; high-quality evidence.)



Intraoperative Risk Factors Perioperative Appropriate Antibiotics

The goal of giving antibiotics prior to incision is to allow enough time for the antibiotic to diffuse into the tissues and to develop optimal concentrations of antibiotics in the body.

Surgeon Tools/Recommendations:

Recommendations for optimal timing of antibiotic prophylaxis:

- Within 1 hour prior to surgical procedure, with most surgeons opting for within 30 minutes of incision.
- Vancomycin and fluoroquinolones may be infused up to 2 hours before surgery due to extended infusion times and long half-lives
- Intraoperative redosing of cefazolin is recommended every 4 hours. Alternatives for patients with a true Penicillin allergy (anaphylaxis breathing issues) include clindamycin and vancomycin.
- Important to review antibiograms or consult with infectious disease team members when deciding on a preferred perioperative antibiotic strategy targeted for patient within a specific area or regions.





Preoperative Antibiotic Prophylaxis Timing

- Complete prophylaxis antibiotics 0-60 minutes prior to the surgical incision
- CDC recommendations – “timed such that a **bactericidal concentration** of the agent is established in the serum tissues when the incision is made”
- Re-dose antibiotic if:
 - Surgery greater than 2 half-lives of antibiotic
 - Usually, 4 hours with most common agents Cefotetan and Cefazolin (Cefazolin half life = ~1.8 hours)
 - Significant blood loss (>1L blood loss)





Joint Commission National Quality Core Measures SCIP (Surgical Care Improvement Project)

Measure Set: [Surgical Care Improvement Project \(SCIP\)](#)

Set Measure ID: SCIP-Inf-1

Set Measure ID	Performance Measure Name
SCIP-Inf-1a	Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision - Overall Rate
SCIP-Inf-1b *	Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision - CABG
SCIP-Inf-1c *	Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision - Other Cardiac Surgery
SCIP-Inf-1d *	Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision - Hip Arthroplasty
SCIP-Inf-1e *	Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision - Knee Arthroplasty
SCIP-Inf-1f *	Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision - Colon Surgery
SCIP-Inf-1g *	Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision - Hysterectomy
SCIP-Inf-1h *	Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision - Vascular Surgery

* Joint Commission Only

Performance Measure Name: Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision





Thank you!
Questions?





References

1. Peel TN, Astbury S, Cheng AC, et al. Trial of Vancomycin and Cefazolin as Surgical Prophylaxis in Arthroplasty. *N Engl J Med.* 2023;389(16):1488-1498. doi:10.1056/NEJMoa2301401
2. Sewick A, Makani A, Wu C, O'Donnell J, Baldwin KD, Lee GC. Does dual antibiotic prophylaxis better prevent surgical site infections in total joint arthroplasty?. *Clin Orthop Relat Res.* 2012;470(10):2702-2707. doi:10.1007/s11999-012-2255-1
3. Iannotti F, Prati P, Fidanza A, et al. Prevention of Periprosthetic Joint Infection (PJI): A Clinical Practice Protocol in High-Risk Patients. *Trop Med Infect Dis.* 2020;5(4):186. Published 2020 Dec 11. doi:10.3390/tropicalmed5040186
4. Pichichero, M Penicillin and Cephalosporin Allergy *Annals of Allergy and Asthma immunology* 112 (2014) 404-412
5. Goodman. E Cephalosporins Can be Given to Penicillin-allergic Patients who Do Not Exhibit an Anaphylactic Response, *Journal of Clinical Anesthesia* (2001)13: 6561-564
6. Macy, E Health care use and serious infection prevalence associated penicillin allergy: in hospitalized patients: A cohort study *Journal of Allergy and Clinical immunology* March (2014) pp 790-796
7. Mcfadden, D Impact of Reported Beta-lactam Allergy on Inpatient Outcomes: A Multicenter Prospective Cohort Study *Clinical Infectious Disease* (2016) October 1 pp 904-910
8. Macy, E Penicillin and Beta-lactam Allergy: Epidemiology and Diagnosis, *Current Allergy and Asthma Rep* (2014) 14:476
9. Kurcz BP, Allan DG, Nestler AJ, et al. Documented Penicillin Allergies Should Not Preclude Use of Preoperative Cefazolin in Hip and Knee Arthroplasty. *J Am Acad Orthop Surg.* 2023;31(2):e107-e117. doi:10.5435/JAAOS-D-22-00122
10. Berríos-Torres SI, Umscheid CA, Bratzler DW, et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017 [published correction appears in *JAMA Surg.* 2017 Aug 1;152(8):803]. *JAMA Surg.* 2017;152(8):784-791. doi:10.1001/jamasurg.2017.0904

